BNTC Stock — Benitec Biopharma Ltd ADR

Benitec Biopharma Ltd ADR (BNTC)

Updated October 16, 2026.

BNTC is a Stock. Total return is 47.6% over the past 12.3 years, 330.1 points behind SPY at 377.7%.

Benitec Biopharma is a clinical-stage biotechnology company developing novel genetic medicines using its Silence and Replace platform, which combines RNA interference with gene therapy to simultaneously silence disease-causing genes and deliver replacement genes in a single treatment; the company is advancing BB-301, an AAV-based therapy for oculopharyngeal muscular dystrophy. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage genetic medicine development and who can tolerate the substantial risk inherent in clinical-stage biotechnology companies.

BNTC performance versus SPY

Price and return data through 2026-10-16.

Total return is 47.6% over the past 12.3 years, 330.1 points behind SPY at 377.7%. Over the past year its total return — price change plus distributions reinvested — is -48.3%. Its deepest 1-year drawdown was 50.9%.

BNTC key facts

Asset type

Stock

Asset class

Equity

Inception date

06/23/2014

Distribution frequency

None

Last close

$8.11 (as of 2026-10-16)

Market cap

$282,898,908

Average volume

158557.0

Ex-dividend date

06/01/2018

Payment date

06/08/2018

Beta

0.249

Payout ratio

0.0%

EPS

$-0.98

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BNTC risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 50.9%.

Who may consider BNTC — and who may not

It is a weaker fit for investors who need monthly cash flow (BNTC does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BNTC

• All tickers starting with B

Tagged: Healthcare, Dividend.

Frequently asked questions